PTPA and Alzheimer disease: In an AD model cell line (H4-SWE), PPP2R5D-silencing RNA treatment reduced the level of phosphorylation at Thr-231, Ser-202/Thr-205, and Ser-422, indicating that the PP2A–PPP2R5D holoenzyme activates a few tau-specific kinases.